Literature DB >> 20379818

Systemic sclerosis sine scleroderma associated with antiphospholipid syndrome.

Pollyanna d'Ávila Leite1, Jozélio Freire de Carvalho.   

Abstract

The antiphospholipid syndrome (APS) can be primary, when it occurs alone, or secondary, when it is associated with another autoimmune disease, mainly systemic lupus erythematosus and rarely other autoimmune diseases. Cases described in literature (Medline 1966 to December 2009) associate the presence of antiphospholipid antibodies with the presence of APS and systemic sclerosis (SS). Currently, however, no cases of the SS variant sine scleroderma with APS have been described. In this study, the authors describe the case of a patient with APS characterised by thrombosis of the retinal veins, in May 2006, the presence of lupus anticoagulant and an anticardiolipin IgG antibody. In May 2007, this patient developed Raynaud's phenomenon, a lack of oesophageal motility and nailfold capillaroscopy with a scleroderma pattern. The patient was positive for the anti-centromere antibody but lacked any evidence of cutaneous thickening or involvement. In summary, the authors describe the first case of a patient with APS associated with SS sine scleroderma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20379818     DOI: 10.1007/s00296-010-1482-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  22 in total

1.  Acute interstitial pneumonia associated with antiphospholipid syndrome in a patient with systemic sclerosis.

Authors:  M Minatani; J Takasaki; H Iwata; M Kinoshita; S Aotsuka; M Sumiya
Journal:  Clin Exp Rheumatol       Date:  2000 Nov-Dec       Impact factor: 4.473

2.  More on anticardiolipin and anti-beta2 glycoprotein I in systemic sclerosis.

Authors:  C M Antonioli; E Danieli; P Airò; R Cattaneo; A Tincani
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

3.  Anticardiolipin antibodies in systemic sclerosis.

Authors:  V Fonollosa; A Selva; J Lima; C P Simeon; M Vilardell
Journal:  J Am Acad Dermatol       Date:  1991-07       Impact factor: 11.527

Review 4.  Large vessel arterial thrombosis in systemic sclerosis associated with antiphospholipid antibodies.

Authors:  L S Shapiro
Journal:  J Rheumatol       Date:  1990-05       Impact factor: 4.666

5.  Anticardiolipin antibodies in systemic sclerosis: immunological and clinical associations.

Authors:  R G Malia; M Greaves; L M Rowlands; A C Lawrence; A Hume; N R Rowell; J Moult; C M Holt; N Lindsey; P Hughes
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

6.  Clinical manifestations in anticardiolipin antibody-positive patients with progressive systemic sclerosis.

Authors:  I Katayama; K Otoyama; S Kondo; K Nishioka; S Nishiyama
Journal:  J Am Acad Dermatol       Date:  1990-08       Impact factor: 11.527

7.  Primary antiphospholipid syndrome with and without Sneddon's syndrome.

Authors:  Cezar Augusto Muniz Caldas; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

8.  Antiphospholipid syndrome in scleroderma.

Authors:  R Whittaker; A Barnett; P Ryan
Journal:  J Rheumatol       Date:  1993-09       Impact factor: 4.666

9.  Clinical significance of anticardiolipin antibodies in patients with systemic sclerosis.

Authors:  U Picillo; S Migliaresi; M R Marcialis; A M Ferruzzi; G Tirri
Journal:  Autoimmunity       Date:  1995       Impact factor: 2.815

10.  Coexistence of five autoimmune diseases: diagnostic and therapeutic difficulties.

Authors:  Ewa Wielosz; Maria Majdan; Iwona Zychowska; Radosław Jeleniewicz
Journal:  Rheumatol Int       Date:  2008-03-05       Impact factor: 2.631

View more
  1 in total

1.  Antiphospholipid antibodies and systemic scleroderma.

Authors:  Awa Oumar Touré; Fatimata Ly; Abibatou Sall; Alassane Diatta; Macoura Gadji; Moussa Seck; Blaise Faye; Tandakha Dieye; Saliou Diop
Journal:  Turk J Haematol       Date:  2013-03-05       Impact factor: 1.831

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.